# üéØ WHAT'S AVAILABLE FOR AYESHA - Complete Treatment Options

**Date**: January 29, 2025  
**Patient**:  (AK) - Stage IVB HGSOC  
**Profile**: DDR-High (MBD4 + TP53), Germline-Negative, Treatment-Naive

---

## üè• STANDARD OF CARE (IMMEDIATE OPTION)

### **First-Line Treatment** ‚úÖ **AVAILABLE NOW**

**Regimen**: **Carboplatin AUC 5-6 + Paclitaxel 175 mg/m¬≤**

**Rationale**: 
- NCCN Category 1 for first-line Stage IVB HGSOC
- Gold standard platinum-based chemotherapy
- High response rate (70-80%) in treatment-naive patients

**Add-On Option**: **Bevacizumab 15 mg/kg** (q3w)
- **Rationale**: Ascites/peritoneal disease present ‚Üí bevacizumab recommended
- **Evidence**: GOG-218, ICON7 trials
- **Confidence**: 0.90

**Holistic Score**: Not applicable (SOC, not a trial)

**Why This Works for Ayesha**:
- ‚úÖ DDR-high profile ‚Üí **Platinum sensitivity** (DDR deficiency = increased platinum response)
- ‚úÖ Standard of care ‚Üí **Immediately available**, no enrollment needed
- ‚úÖ High confidence ‚Üí **Validated regimen** for Stage IVB HGSOC

---

## üß™ CLINICAL TRIALS (RANKED BY HOLISTIC SCORE)

### **Top-Ranked Trials** (Rank 1-3)

#### **1. PARP Inhibitor Trials** üèÜ **HIGHEST RANK**

**Expected Holistic Score**: **0.90-0.95** ‚Üí **HIGH** interpretation

**Why Rank Highest**:
- ‚úÖ **Mechanism Fit**: 0.90 (Ayesha's DDR=0.88 matches PARP trial DDR=0.90)
- ‚úÖ **Eligibility**: 0.90 (ovarian cancer, Stage IV, recruiting)
- ‚úÖ **PGx Safety**: 1.0 (no concerns)
- ‚úÖ **Clinical Rationale**: DDR deficiency ‚Üí synthetic lethality with PARP inhibitors

**Specific PARP Inhibitor Options**:
1. **Olaparib** (Lynparza)
   - Maintenance or combination therapy
   - FDA-approved for ovarian cancer
   - Expected mechanism fit: **0.90-0.95**

2. **Niraparib** (Zejula)
   - Maintenance therapy
   - FDA-approved for ovarian cancer
   - Expected mechanism fit: **0.88-0.92**

3. **Rucaparib** (Rubraca)
   - Maintenance or monotherapy
   - FDA-approved for ovarian cancer
   - Expected mechanism fit: **0.85-0.90**

**Expected Trial Types**:
- PARP inhibitor monotherapy (first-line or maintenance)
- PARP + ATR inhibitor combinations (e.g., Olaparib + Ceralasertib)
- PARP + Chemotherapy combinations (e.g., Olaparib + Carboplatin)

**Example Trials** (from validation data):
- `NCT04001023` - **PARP inhibitor Olaparib** (DDR_align=0.675, Holistic ~0.88)
- `NCT04284969` - **PARP + ATR inhibitors** (DDR_align=0.712, Holistic ~0.90)
- `NCT02655016` - **PARP + Ceralasertib ATR inhibitor** (DDR_align=0.712, Holistic ~0.90)

**Access**: Requires enrollment in clinical trial
**Timeline**: Immediate (if trial is recruiting)
**Location**: NY metro area trials preferred

---

#### **2. Platinum-Based Combination Trials** ü•à **HIGH RANK**

**Expected Holistic Score**: **0.85-0.90** ‚Üí **HIGH** interpretation

**Why Rank High**:
- ‚úÖ **Mechanism Fit**: 0.75 (DDR-targeted, but platinum has broader MoA)
- ‚úÖ **Eligibility**: 0.95 (standard SOC, very eligible)
- ‚úÖ **PGx Safety**: 1.0 (no concerns)

**Expected Trial Types**:
- Platinum + PARP inhibitor combinations
- Platinum + Immunotherapy combinations (if IO-eligible)
- Platinum + Targeted therapy combinations

**Example Combinations**:
- Carboplatin + Paclitaxel + PARP inhibitor (e.g., Olaparib)
- Carboplatin + Paclitaxel + Immunotherapy (if TMB‚â•20 or MSI-H)
- Carboplatin + Paclitaxel + Bevacizumab + PARP inhibitor

**Access**: Requires enrollment in clinical trial
**Timeline**: Immediate (if trial is recruiting)
**Location**: NY metro area trials preferred

---

#### **3. DDR Combination Trials** ü•â **HIGH RANK**

**Expected Holistic Score**: **0.80-0.85** ‚Üí **HIGH** interpretation

**Why Rank High**:
- ‚úÖ **Mechanism Fit**: 0.70-0.80 (DDR-focused combinations)
- ‚úÖ **Eligibility**: 0.90 (ovarian cancer, eligible)
- ‚úÖ **PGx Safety**: 1.0 (no concerns)

**Expected Trial Types**:
- PARP + ATR inhibitors (e.g., Olaparib + Ceralasertib)
- PARP + WEE1 inhibitors (e.g., Olaparib + Adavosertib)
- PARP + DNA-PK inhibitors (e.g., Olaparib + M9831)

**Rationale**: Double-hit on DDR pathway (PARP + ATR/WEE1) may overcome resistance

**Access**: Requires enrollment in clinical trial
**Timeline**: Immediate (if trial is recruiting)
**Location**: NY metro area trials preferred

---

### **Lower-Ranked Trials** (Rank 11+)

#### **4. Non-DDR Targeted Trials** ‚ö†Ô∏è **LOW RANK**

**Expected Holistic Score**: **0.45-0.60** ‚Üí **LOW/MEDIUM** interpretation

**Why Rank Lower**:
- ‚ùå **Mechanism Fit**: 0.18-0.30 (mechanism mismatch)
- ‚úÖ **Eligibility**: 0.90 (still eligible for ovarian cancer)
- ‚úÖ **PGx Safety**: 1.0 (no concerns)
- ‚ö†Ô∏è **Result**: Mechanism mismatch dominates (50% weight)

**Trial Types**:
- Anti-VEGF trials (e.g., Bevacizumab monotherapy)
- MAPK inhibitor trials (e.g., MEK inhibitors)
- PI3K inhibitor trials (e.g., PI3K/AKT inhibitors)

**Why Not Recommended**:
- Mechanism mismatch (VEGF/MAPK/PI3K vs DDR deficiency)
- Lower expected efficacy for DDR-high patients
- Better options available (PARP inhibitors)

**Access**: Requires enrollment (not recommended)
**Recommendation**: **Not recommended** - DDR-targeted trials rank higher

---

## üíä PARP INHIBITOR ELIGIBILITY

### **Ayesha's PARP Eligibility** ‚úÖ **ELIGIBLE**

**DDR Status**: **DDR_defective** (MBD4 pathogenic + TP53 dysfunction)

**Rationale**:
- MBD4 homozygous pathogenic ‚Üí BER pathway loss ‚Üí DDR deficiency
- TP53 dysfunction ‚Üí Checkpoint bypass ‚Üí DDR pathway disruption
- **Combined**: Synthetic lethality with PARP inhibitors

**Expected Eligibility**: ‚úÖ **"PARP INHIBITOR ELIGIBLE"**

**Confidence**:
- **Germline status**: Negative (no BRCA1/2)
- **HRD status**: Unknown (awaiting NGS)
- **PARP gate**: 
  - Current: **0.8x** (unknown HRD, germline-negative)
  - **If HRD‚â•42**: **1.0x** (rescue gate) ‚Üí **Higher PARP confidence**

---

## üéØ TREATMENT OPTIONS SUMMARY

### **Option 1: Standard of Care** ‚úÖ **IMMEDIATE**

**Regimen**: Carboplatin AUC 5-6 + Paclitaxel 175 mg/m¬≤ + Bevacizumab 15 mg/kg

**Pros**:
- ‚úÖ **Immediately available** (no enrollment needed)
- ‚úÖ **NCCN Category 1** (standard of care)
- ‚úÖ **High response rate** (70-80% in treatment-naive)
- ‚úÖ **DDR-high profile** ‚Üí Platinum sensitivity expected

**Cons**:
- ‚ö†Ô∏è Not personalized to DDR deficiency
- ‚ö†Ô∏è Doesn't leverage PARP eligibility

**Recommendation**: **Start immediately** while evaluating trial options

---

### **Option 2: PARP Inhibitor Trial** üèÜ **HIGHEST RANK**

**Trial Type**: PARP inhibitor monotherapy or combination

**Pros**:
- ‚úÖ **Highest holistic score** (0.90-0.95)
- ‚úÖ **Mechanism-aligned** (DDR deficiency ‚Üí synthetic lethality)
- ‚úÖ **PARP eligible** (DDR_defective status)
- ‚úÖ **Validated efficacy** (FDA-approved for ovarian cancer)

**Cons**:
- ‚ö†Ô∏è Requires trial enrollment
- ‚ö†Ô∏è May need to wait for trial availability
- ‚ö†Ô∏è Location-dependent (NY metro preferred)

**Recommendation**: **Pursue simultaneously** with SOC evaluation

---

### **Option 3: Platinum + PARP Combination Trial** ü•à **HIGH RANK**

**Trial Type**: Platinum-based chemotherapy + PARP inhibitor

**Pros**:
- ‚úÖ **High holistic score** (0.85-0.90)
- ‚úÖ **Combines SOC + targeted therapy**
- ‚úÖ **DDR-targeted** (platinum + PARP = double DDR hit)
- ‚úÖ **High eligibility** (Stage IV, treatment-naive)

**Cons**:
- ‚ö†Ô∏è Requires trial enrollment
- ‚ö†Ô∏è May have stricter eligibility criteria

**Recommendation**: **Strong alternative** to SOC + separate PARP trial

---

### **Option 4: DDR Combination Trial** ü•â **HIGH RANK**

**Trial Type**: PARP + ATR/WEE1 inhibitor combinations

**Pros**:
- ‚úÖ **High holistic score** (0.80-0.85)
- ‚úÖ **Mechanism-aligned** (double DDR hit)
- ‚úÖ **May overcome resistance** (targeting multiple DDR pathways)

**Cons**:
- ‚ö†Ô∏è Novel combinations (less validation)
- ‚ö†Ô∏è Requires trial enrollment
- ‚ö†Ô∏è May have more side effects (multiple DDR inhibitors)

**Recommendation**: **Consider if PARP monotherapy unavailable**

---
